Abstract
Introduction
The biologic anti-tumour necrosis factor alpha (anti-TNFα) agents infliximab and adalimumab are monoclonal antibodies with binding specificity to TNFα, which are used for the treatment of Crohn’s disease. Clinical response is varied from complete with mucosal healing, to primary non-response, loss of response and adverse drug reactions. Measuring trough blood levels of infliximab and adalimumab may guide clinical management. The sample handling requirements for infliximab and adalimumab were previously unknown.
Aim
The aim of this study was to determine the
Methods
Samples were stored as clotted whole blood or serum at room temperature for up to seven days, before being frozen (−20℃) and analysed as a batch for either infliximab or adalimumab.
Results
No significant difference between the concentration of infliximab and adalimumab measured in samples stored as serum or whole blood for seven days at room temperature, as compared to baseline was found (
Conclusion
The stability of infliximab and adalimumab at room temperature for seven days allows samples to be posted direct from clinics and research centres to the analysing laboratory.
Get full access to this article
View all access options for this article.